Creatine and creatinine metabolism.

F. Hoffmann-La Roche, Vitamins and Fine Chemicals Division, Basel, Switzerland.
Physiological Reviews (Impact Factor: 29.04). 08/2000; 80(3):1107-213.
Source: PubMed

ABSTRACT The goal of this review is to present a comprehensive survey of the many intriguing facets of creatine (Cr) and creatinine metabolism, encompassing the pathways and regulation of Cr biosynthesis and degradation, species and tissue distribution of the enzymes and metabolites involved, and of the inherent implications for physiology and human pathology. Very recently, a series of new discoveries have been made that are bound to have distinguished implications for bioenergetics, physiology, human pathology, and clinical diagnosis and that suggest that deregulation of the creatine kinase (CK) system is associated with a variety of diseases. Disturbances of the CK system have been observed in muscle, brain, cardiac, and renal diseases as well as in cancer. On the other hand, Cr and Cr analogs such as cyclocreatine were found to have antitumor, antiviral, and antidiabetic effects and to protect tissues from hypoxic, ischemic, neurodegenerative, or muscle damage. Oral Cr ingestion is used in sports as an ergogenic aid, and some data suggest that Cr and creatinine may be precursors of food mutagens and uremic toxins. These findings are discussed in depth, the interrelationships are outlined, and all is put into a broader context to provide a more detailed understanding of the biological functions of Cr and of the CK system.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to analyze the level of creatine use along with the perceived benefits and barriers of creatine use among collegiate athletes who participate in throwing events within the sport of track and field. A total of 258 throwers from NCAA Division I institutions completed an online survey regarding creatine. The results provided baseline levels of creatine use and allowed for analysis of factors related to athletic conference affiliation. Results indicate that creatine use remains to be a common (32.7%) practice among throwers with significantly higher levels of use among Football Bowl Subdivision (FBS) conference athletes (44.6%) than Football Championship Subdivision (FCS) conference athletes (28.8%), [chi]2 = 5.505, p = .019. The most common reasons for using creatine included a desire to improve/increase: strength (83.3%), recovery time (69.0%), and performance (60.7%). The most common perceived obstacles included: contamination/quality control (39.5%), cost (33.3%), inconvenience (16.7%), and cramping (14.3%). A desire for additional education and training was noted through an expression of interest (55.6%) with significantly higher levels of interest from FBS athletes (65.6%) than FCS athletes (52.2%), [chi]2 = 6.425, p = .039. However, the athletic departments provide nutritional supplement counseling at only 26.6% of the schools. While the access to full-time nutritionist counsel was available at 57.3% of the schools, there was a significant difference ([chi]2 = 9.096, p = .003) between FBS schools (73.7%) and FCS schools (51.7%).
    The Journal of Strength and Conditioning Research 12/2014; · 1.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A B S T R A C T Guanidinoacetic acid (GAA) is a suitable feed additive yet its possible application in human nutrition as a food supplement requires preliminary pharmacokinetics data. The aim of the present study was to explore the effects of an acute oral dose of GAA on serum GAA, cre-atine (Cr), creatinine (Crn), and total homocysteine (T-Hcy) concentration-time profiles and urinary excretion rates of GAA, Cr and Crn. Twenty-four young healthy participants (age 22.3 ± 1.3 years; 12 males and 12 females) voluntarily ingested a single dose of GAA (2.4 g) or placebo (inulin) followed by the serial measurement of serum GAA, Cr, Crn and T-Hcy and urinary GAA, Cr and Crn concentration within the next 24 h. In response to GAA inges-tion a substantial rise in serum GAA and Cr concentration was observed occurring 1 h after the ingestion (peak value of 144.9 ± 24.8 lmol/L and 65.5 ± 18.6 lmol/L, respectively). The Crn serum profile for 24 h was not affected by 2.4 g GAA ingestion, showing a peak value of 90.1 ± 12.2 lmol/L 1 h post-administration. A single dose of GAA induced a notable rise in serum T-Hcy by about 40%. The peak value was observed 12 h post administration (13.1 ± 2.1 lmol/L). Urinary excretion for GAA and Cr peaked after 4 h (453.1 ± 235.0 mg/L and 40.8 ± 33.3 mg/L, respectively). Crn excretion in urine remained unchanged after GAA administration. In conclusion, orally ingested GAA was readily bioavailable and was trans-formed to Cr. Serum T-Hcy kinetics proofed to be sensitive to acute GAA intake. Trial iden-tification: number NCT01133899.
    Journal of Functional Foods 01/2014; 6(2014):598-605. · 4.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in the creatine (Cr) transporter (CrT) gene lead to cerebral creatine deficiency syndrome-1 (CCDS1), an X-linked metabolic disorder characterized by cerebral Cr deficiency causing intellectual disability, seizures, movement and behavioral disturbances, language and speech impairment ( OMIM #300352). CCDS1 is still an untreatable pathology that can be very invalidating for patients and caregivers. Only two murine models of CCDS1, one of which is an ubiquitous knockout mouse, are currently available to study the possible mechanisms underlying the pathologic phenotype of CCDS1 and to develop therapeutic strategies. Given the importance of validating phenotypes and efficacy of promising treatments in more than one mouse model we have generated a new murine model of CCDS1 obtained by ubiquitous deletion of 5-7 exons in the Slc6a8 gene. We showed a remarkable Cr depletion in the murine brain tissues and cognitive defects, thus resembling the key features of human CCDS1. These results confirm that CCDS1 can be well modeled in mice. This CrT (-/y) murine model will provide a new tool for increasing the relevance of preclinical studies to the human disease.
    F1000Research. 01/2014; 3:228.


Available from